ReviewAnalytical cellular pathology (Amsterdam)2025
Toward Precision Medicine in Celiac Disease: Emerging Roles of Multiomics and Artificial Intelligence.
Review in Analytical cellular pathology (Amsterdam), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper focuses on celiac disease (CD), an autoimmune disorder characterized by small intestinal enteropathy and gastrointestinal symptoms. The prevalence of CD is rising, and there is a need for prompt and accurate diagnosis. The paper discusses the challenges in classifying CD and the consequences of delayed diagnosis, including increased morbidity and mortality rates. It also highlights the Marsh classification, which categorizes CD based on histological characteristics. However, this classification has limitations, which can lead to misdiagnosis. The emergence of multiomics data and artificial intelligence (AI) is presented as a potential solution to improve CD diagnosis and management. Multiomics data integration enables a more precise diagnosis, while AI and machine learning (ML) techniques facilitate the identification of clinically relevant patterns and the development of diagnostic models. According to the findings, the integration of AI and multiomics data holds transformative potential for the diagnosis and management of CD, facilitating early diagnosis and personalized treatment strategies. AI-assisted methods, including video capsule endoscopy (VCE) analysis, have shown sensitivities exceeding 90%, enhancing diagnostic accuracy while reducing invasiveness. As novel biomarkers are identified, individualized management approaches can evolve, leading to improved patient outcomes, though further efforts are needed to standardize these technologies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.